567 related articles for article (PubMed ID: 29793000)
1. Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
Lee YS; Gupta R; Kwon JT; Cho DC; Seo YJ; Seu SY; Park EK; Han I; Kim CH; Sung JK; Kim KT
Spine J; 2018 Oct; 18(10):1877-1887. PubMed ID: 29793000
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
3. A synergistic bone sparing effect of curcumin and alendronate in ovariectomized rat.
Cho DC; Kim KT; Jeon Y; Sung JK
Acta Neurochir (Wien); 2012 Dec; 154(12):2215-23. PubMed ID: 23053289
[TBL] [Abstract][Full Text] [Related]
4. Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study.
Chavassieux P; Garnero P; Duboeuf F; Vergnaud P; Brunner-Ferber F; Delmas PD; Meunier PJ
J Bone Miner Res; 2001 Jan; 16(1):89-96. PubMed ID: 11149494
[TBL] [Abstract][Full Text] [Related]
5. Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats.
Bourrin S; Ammann P; Bonjour JP; Rizzoli R
Bone; 2002 Jan; 30(1):195-200. PubMed ID: 11792585
[TBL] [Abstract][Full Text] [Related]
6. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
[TBL] [Abstract][Full Text] [Related]
7. Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
Iwamoto J; Yeh JK; Schmidt A; Rowley E; Stanfield L; Takeda T; Sato M
Calcif Tissue Int; 2005 Aug; 77(2):119-26. PubMed ID: 16059775
[TBL] [Abstract][Full Text] [Related]
8. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
Kangas L; Härkönen P; Väänänen K; Peng Z
Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
[TBL] [Abstract][Full Text] [Related]
9. Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats.
Luo Y; Zhang L; Wang WY; Hu QF; Song HP; Su YL; Zhang YZ
Bone; 2013 Aug; 55(2):439-48. PubMed ID: 23500174
[TBL] [Abstract][Full Text] [Related]
10. Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys.
Hotchkiss CE; Stavisky R; Nowak J; Brommage R; Lees CJ; Kaplan J
Bone; 2001 Jul; 29(1):7-15. PubMed ID: 11472885
[TBL] [Abstract][Full Text] [Related]
11. The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats.
Ammann P; Bourrin S; Bonjour JP; Brunner F; Meyer JM; Rizzoli R
Osteoporos Int; 1999; 10(5):369-76. PubMed ID: 10591834
[TBL] [Abstract][Full Text] [Related]
12. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.
Weinstein RS; Parfitt AM; Marcus R; Greenwald M; Crans G; Muchmore DB
Osteoporos Int; 2003 Oct; 14(10):814-22. PubMed ID: 14610642
[TBL] [Abstract][Full Text] [Related]
13. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
14. A SERM increasing the expression of the osteoblastogenesis and mineralization-related proteins and improving quality of bone tissue in an experimental model of osteoporosis.
Yogui FC; Momesso GAC; Faverani LP; Polo TOB; Ramalho-Ferreira G; Hassumi JS; Rossi AC; Freire AR; Prado FB; Okamoto R
J Appl Oral Sci; 2018; 26():e20170329. PubMed ID: 29742257
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of modal damping factor as a diagnostic tool for osteoporosis and its relation with serum osteocalcin and collagen I N-telopeptide for monitoring the efficacy of alendronate in ovariectomized rats.
Christopoulou GE; Stavropoulou A; Anastassopoulos G; Panteliou SD; Papadaki E; Karamanos NK; Panagiotopoulos E
J Pharm Biomed Anal; 2006 Jun; 41(3):891-7. PubMed ID: 16488571
[TBL] [Abstract][Full Text] [Related]
16. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
[TBL] [Abstract][Full Text] [Related]
17. Development and application of a serum C-telopeptide and osteocalcin assay to measure bone turnover in an ovariectomized rat model.
Srivastava AK; Bhattacharyya S; Castillo G; Wergedal J; Mohan S; Baylink DJ
Calcif Tissue Int; 2000 Jun; 66(6):435-42. PubMed ID: 10821880
[TBL] [Abstract][Full Text] [Related]
18. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
Delmas PD; Davis SR; Hensen J; Adami S; van Os S; Nijland EA
Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
[TBL] [Abstract][Full Text] [Related]
19. Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol.
Bitto A; Burnett BP; Polito F; Marini H; Levy RM; Armbruster MA; Minutoli L; Di Stefano V; Irrera N; Antoci S; Granese R; Squadrito F; Altavilla D
Br J Pharmacol; 2008 Nov; 155(6):896-905. PubMed ID: 18695641
[TBL] [Abstract][Full Text] [Related]
20. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Schmidt A; Hoover J; Cole HW; Yao W; Jee WS; Sato M
Endocrinology; 2003 May; 144(5):2008-15. PubMed ID: 12697709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
